Long-term efficacy and safety of early alogliptin initiation in subjects with type 2 diabetes: an extension of the SPEAD-A study

We previously reported in the study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A) that alogliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, attenuated the progression of carotid atherosclerosis in subjects with type 2 diabetes and no history of cardiovascular disease....

Descripción completa

Detalles Bibliográficos
Autores principales: Mita, Tomoya, Katakami, Naoto, Yoshii, Hidenori, Onuma, Tomio, Kaneto, Hideaki, Osonoi, Takeshi, Shiraiwa, Toshihiko, Yasuda, Tetsuyuki, Umayahara, Yutaka, Yamamoto, Tsunehiko, Yokoyama, Hiroki, Kuribayashi, Nobuichi, Jinnouchi, Hideaki, Gosho, Masahiko, Shimomura, Iichiro, Watada, Hirotaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480471/
https://www.ncbi.nlm.nih.gov/pubmed/37669959
http://dx.doi.org/10.1038/s41598-023-41036-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480471/
https://www.ncbi.nlm.nih.gov/pubmed/37669959
http://dx.doi.org/10.1038/s41598-023-41036-1

Ejemplares similares